Recent pharmacological advances in the management of gout.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28968896.
- Also identified by DOI 10.1093/rheumatology/kex343.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gout is the most common cause of inflammatory arthritis worldwide, and reports show that despite availability of therapies, management is still suboptimal. The new EULAR 2016 recommendations for the treatment of gout highlight the huge development in gout therapies, and the number of drugs being trialled only continues to increase. A clinical review of the evidence that underlies the recommendations from EULAR can reveal possible gaps in the literature and avenues for future research into gout therapies.
Medical subject headings
- Disease Management
- Evidence-Based Medicine
- Gout
- Gout Suppressants